Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months. We retrospectively analyzed the value of individualized multimodal immunotherapy (IMI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Gool, Stefaan W., Makalowski, Jennifer, Bitar, Michael, Van de Vliet, Peter, Schirrmacher, Volker, Stuecker, Wilfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758045/
https://www.ncbi.nlm.nih.gov/pubmed/35173295
http://dx.doi.org/10.1038/s41435-022-00162-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758045/
https://www.ncbi.nlm.nih.gov/pubmed/35173295
http://dx.doi.org/10.1038/s41435-022-00162-y

Ejemplares similares